Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.

Gavrilov, Sergey; Zhudenkov, Kirill; Helmlinger, Gabriel; Dunyak, James; Peskov, Kirill; Aksenov, Sergey

Gavrilov, Sergey; Zhudenkov, Kirill; Helmlinger, Gabriel; Dunyak, James; Peskov, Kirill; Aksenov, Sergey.

Affiliation

Gavrilov S; M&S Decisions LLC, Moscow, Russia.
Zhudenkov K; Faculty CMC of Lomonosov MSU, Moscow, Russia.
Helmlinger G; M&S Decisions LLC, Moscow, Russia.
Dunyak J; M&S Decisions LLC, Moscow, Russia.
Peskov K; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
Aksenov S; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.

CPT Pharmacometrics Syst Pharmacol ; 10(1): 67-74, 2021 01.

Article in En | MEDLINE | ID: mdl-33319498

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphocytes / Carcinoma, Non-Small-Cell Lung / Tumor Burden / Antineoplastic Agents, Immunological / Lung Neoplasms / Models, Biological / Antibodies, Monoclonal / Neutrophils Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2021 Document type: Article Affiliation country: Rusia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google